Tags : Immuno-Oncology Therapies

Gilead Signs an Agreement with Carna Biosciences to Develop and

Shots: Carna to receive $20M upfront, up to $450M as development & commercial milestones and royalties on sales. Gilead to get WW rights to develop and commercialize inhibitors against immuno-oncology target and an exclusive right to access Carna’s lipid kinase drug discovery platform The focus of the collaboration is to advance novel immunotherapies targeting cancer […]Read More

Eli Lilly and NextCure Signs a Multi-Year Collaboration to Develop

Shots: NextCure to get $25M upfront plus milestones & royalty payments in addition to $15M equity investments. NextCure & Lilly will hold equal rights to exclusively license the Abs The focus of the agreement is to develop novel immunotherapies using NextCure’s FIND-IO technology in the fields of oncology FIND-IO platform has ability to identify cell […]Read More